Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma
OTHER: Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Progression-free survival (PFS) at 1 year after transplantation, The time from the end of transplantation to progression of disease or death at 1year, Participants will be followed for an expected average of 1 years after transplantation
This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma